Evidence map›Paper›PMID 28270605›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2017

Phosphoproteins in extracellular vesicles as candidate markers for breast cancer.

I-Hsuan Chen, Liang Xue, Chuan-Chih Hsu, Juan Sebastian Paez Paez, Li Pan, Hillary Andaluz, Michael K Wendt, Anton B Iliuk, Jian-Kang Zhu, W Andy Tao

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 222 papers.

0numbers the graph read from it
0cells of the map it votes in
222citing papers in PubMed
16.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

222 citing papers in PubMed, 486 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Proteome of CD9Life (Basel, Switzerland) · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

162 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

I-Hsuan ChenDepartment of Biochemistry, Purdue University, West Lafayette, IN 47907.
Liang XueDepartment of Biochemistry, Purdue University, West Lafayette, IN 47907.
Chuan-Chih HsuDepartment of Biochemistry, Purdue University, West Lafayette, IN 47907.
Juan Sebastian Paez PaezDepartment of Biochemistry, Purdue University, West Lafayette, IN 47907.
Li PanDepartment of Medicinal Chemistry & Molecular Pharmacology, Purdue University, West Lafayette, IN 47907.
Hillary AndaluzDepartment of Chemistry, Purdue University, West Lafayette, IN 47907.
Michael K WendtDepartment of Medicinal Chemistry & Molecular Pharmacology, Purdue University, West Lafayette, IN 47907.
Anton B IliukDepartment of Innovations, Tymora Analytical Operations, West Lafayette, IN 47906.
Jian-Kang ZhuDepartment of Biochemistry, Purdue University, West Lafayette, IN 47907; jkzhu@purdue.edu watao@purdue.edu.ORCID 0000-0001-5134-731X
W Andy TaoDepartment of Biochemistry, Purdue University, West Lafayette, IN 47907; jkzhu@purdue.edu watao@purdue.edu.
Purdue University West Lafayette · USChinese Academy of Sciences · CNTymora Analytical Operations (United States) · US

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI John Tesmer · 1985 to 2026
$43.4M
New Proteomic Technologies for the Analysis of Tyrosine Kinase Signaling PathwaysR01GM088317 · NIGMS · PURDUE UNIVERSITY · PI TAO, W. ANDY · 2010 to 2014
$1.6M
A Proteomic Platform to identify and Validate Biomarkers in Metabolic Syndrome and Coronary Artery DiseaseR01GM111788 · NIGMS · PURDUE UNIVERSITY · PI TAO, W. ANDY · 2015 to 2017
$900k
Metal ion-functionalized soluble nanopolymers: A new analytical platform for plasR41GM109626 · NIGMS · TYMORA ANALYTICAL OPERATIONS, LLC · PI TAO, W. ANDY · 2014 to 2015
$641k
Developing novel RPPA for the detection of metastatic prostate cancerR41CA210772 · NCI · TYMORA ANALYTICAL OPERATIONS, LLC · PI TAO, W. ANDY · 2016 to 2018
$227k
NCI NIH HHS P30 CA023168NCI NIH HHS R41 CA210772NIGMS NIH HHS R01 GM088317NIGMS NIH HHS R01 GM111788NIGMS NIH HHS R41 GM109626
6 · The paper itself

Abstract

The state of protein phosphorylation can be a key determinant of cellular physiology such as early-stage cancer, but the development of phosphoproteins in biofluids for disease diagnosis remains elusive. Here we demonstrate a strategy to isolate and identify phosphoproteins in extracellular vesicles (EVs) from human plasma as potential markers to differentiate disease from healthy states. We identified close to 10,000 unique phosphopeptides in EVs isolated from small volumes of plasma samples. Using label-free quantitative phosphoproteomics, we identified 144 phosphoproteins in plasma EVs that are significantly higher in patients diagnosed with breast cancer compared with healthy controls. Several biomarkers were validated in individual patients using paralleled reaction monitoring for targeted quantitation. This study demonstrates that the development of phosphoproteins in plasma EV as disease biomarkers is highly feasible and may transform cancer screening and monitoring.

Indexed as

Biomarkers, TumorBiomarkersBlood ProteinsBreast NeoplasmsCase-Control StudiesCluster AnalysisComputational BiologyExosomesExtracellular VesiclesFemaleHumansPhosphopeptidesPhosphoproteinsProteomeProteomicsReproducibility of ResultsBiomarkersBiomarkers, TumorBlood ProteinsPhosphopeptidesPhosphoproteinsProteomebiomarkerextracellular vesiclesmass spectrometryphosphoproteinsproteomics

Identifiers

PMID28270605
PMCPMC5373352
OpenAlexW2594408608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.